natgillin/translations-raw huggingface dataset:
Content of the pack and other information What Axura contains 
Sadržaj pakiranja i druge informacije Što Axura sadrži
In particular, Axura may change the effects of the following medicines and their dose may need to be adjusted by your doctor: 
Posebice, Axura može promijeniti učinak sljedećih lijekova, te će liječnik možda morati prilagoditi njihovu dozu:
What Axura looks like and contents of the pack 
Kako Axura izgleda i sadržaj pakiranja
The Axura treatment initiation pack is only to be used for the beginning of the treatment with Axura. 
Pakovanje ovaj lijek za početak liječenja se treba koristiti samo na početku liječenja Axurom.
If you go into hospital, let your doctor know that you are taking Axura. 
Ako dođete u bolnicu, obavijestite svog liječnika da uzimate Axuru.
Axura belongs to a group of medicines known as anti-dementia medicines. 
Axura se ubraja u skupinu lijekova poznatih kao lijekovi protiv demencije.
If you forget to take Axura 
Ako ste zaboravili uzeti Axuru
Axura contains sorbitol 
Axura sadrži sorbitol
Also, Axura may change your reactivity, making driving or operating machinery inappropriate. 
Axura također može promijeniti Vašu sposobnost reagiranja, što čini upravljanje vozilima i rad sa strojevima neprikladnima.
Date of first authorisation: 17 May 2002 Date of latest renewal: 17 May 2007 
Datum posljednje obnove: 17. svibanj 2007.
Axura oral solution is available in bottles of 50 ml, 100 ml or a multipack of 500 ml (10 x 50 ml). 
Axura oralna otopina dostupna je u bocama od 50 ml, 100 ml ili višestruko pakiranje od 500 ml (10 x 50 ml).
EU/1/02/218/011 500 ml (10 bottles of 50 ml) 
EU/1/02/218/011 500 ml (10 boca od 50 ml)
The most frequently occurring adverse reactions with a higher incidence in the Axura group than in the placebo group were dizziness (6.3% vs 5.6%, respectively), headache (5.2% vs 3.9%), constipation (4.6% vs 2.6%), somnolence (3.4% vs 2.2%) and hypertension (4.1% vs 2.8%). 
Nuspojave koje su se najčešće pojavljivale s većom incidencijom u skupini bolesnika liječenih Axurom nego u skupini koja je uzimala placebo bile su omaglica (6,3% naspram 5,6%), glavobolja (5,2% naspram 3,9%), konstipacija (4,6% naspram 2,6%), somnolencija (3,4% naspram 2,2%) i hipertenzija (4,1% naspram 2,8%).
Excipients: Each one millilitre of solution contains 100 mg sorbitol (E 420) and 0.5 mg potassium, see section 4.4. 
Pomoćne tvari: svaki mililitar otopine sadrži 100 mg sorbitola (E 420) i 0,5 mg kalija, vidjeti dio 4.4.
These events have been reported in patients treated with Axura. 
Ovi su događaji prijavljivani kod bolesnika liječenih Axurom.
- If you take a large overdose of Axura, contact your doctor or get medical advice, as you may need medical attention. 
Ako ste uzeli preveliku dozu Axure, javite se Vašem liječniku za savjet, jer bi Vam mogla zatrebati medicinska pomoć.
Talk to your doctor or pharmacist before taking Axura - if you have a history of epileptic seizures - if you have recently experienced a myocardial infarction (heart attack), or if you are suffering from congestive heart failure or from an uncontrolled hypertension (high blood pressure). 
Obratite se svom liječniku ili ljekarniku prije nego uzmete Axuru ako u anamnezi imate epileptičke napadaje, - ako ste nedavno imali infarkt miokarda (srčani udar), ili ako bolujete od kongestivnog zatajenja srca ili nekontrolirane hipertenzije (povišeni krvni tlak).
At the beginning of treatment you will start by using Axura 5 mg film-coated tablets once a day. 
Liječenje ćete započeti korištenjem Axura filmom obloženih tableta od 5 mg jedanput na dan.
In patients with mild or moderate hepatic impaired function (Child-Pugh A and Child-Pugh B) no dose adjustment is needed. 
Oštećenje jetrene funkcije Kod bolesnika s blagim ili umjerenim oštećenjem jetrene funkcije (Child-Pugh A i Child-Pugh B) nije potrebna prilagodba doze.
Furthermore, Axura has minor to moderate influence on the ability to drive and use machines such that outpatients should be warned to take special care. 
Nadalje, Axura ima blagi do umjereni utjecaj na sposobnost upravljanja vozilima i rada sa strojevima pa ambulantne bolesnike treba upozoriti da na to obrate posebnu pozornost.
If you suffer from renal impairment (kidney problems), your doctor should closely monitor your kidney function and if necessary adapt the memantine doses accordingly. 
Ako imate oštećenje bubrežne funkcije (probleme s bubrezima), liječnik treba pažljivo funkciju Vaših bubrega i ovisno o njoj, prilagoditi dozu memantina, ako je to potrebno.
What you need to know before you take Axura Do not take Axura 
Što morate znati prije nego počnete uzimati Axuru Nemojte uzimati Axura
Adverse reactions are ranked according to system organ class, using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to 
Nuspojave su razvrstane prema klasifikaciji organskih sustava, konvencijuprema sljedećim skupinama učestalosti: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko
What is Axura used for 
Za što se Axura koristi
What Axura is and what it is used for What you need to know before you take Axura How to take Axura 
Što je Axura i za što se koristi Što morate znati prije nego počnete uzimati Axuru Kako uzimati Axuru
The recommended treatment dose of 20 mg per day is achieved by a gradual increase of the Axura dose during the first 3 weeks of treatment. 
Preporučena doza za liječenje od 20 mg dnevno postiže se postupnim povećanjem doze Axure tijekom prva 3 tjedna liječenja.
Axura should be administered once a day and should be taken at the same time every day. 
Axura se mora primjenjivati jednom dnevno i potrebno ju je uzimati svaki dan u isto vrijeme.
Axura acts on these NMDA-receptors improving the transmission of nerve signals and the memory. 
Axura djeluje na navedene NMDA receptore poboljšavajući prijenos živčanih signala i pamćenje.
What Axura is and what it is used for How does Axura work 
Što je Axura i za što se koristi Kako djeluje Axura
Daily doses of 20 mg lead to steady-state plasma concentrations of memantine ranging from 70 to 150 ng/ml (0.5-1 µmol) with large interindividual variations. 
Dnevne doze od 20 mg dovode do plazmatskih koncentracija memantina u stanju dinamičke ravnoteže u rasponu od 70 do 150 ng/ml (0,5-1 µmol) s velikim interindividualnim razlikama.
Axura should be taken once daily at the same time each day. 
Axura se mora uzimati jednom dnevno, svaki dan u isto vrijeme.
Axura is used for the treatment of patients with moderate to severe Alzheimer's disease. 
Axura se koristi za liječenje bolesnika s umjerenom do teškom Alzheimerovom bolešću.
The solution also contains potassium sorbate and sorbitol (E 420). 
Otopina također sadrži kalijev sorbat i sorbitol (E 420).
The other ingredients are: potassium sorbate, sorbitol (E 420) and purified water. 
Drugi sastojci su: kalijev sorbat, sorbitol E 420 i pročišćena voda.
How to take Axura 
Kako uzimati Axuru
Film-coated tablet. 
Filmom obložene tablete.
Each pack of 28 film-coated tablets for a 4 week treatment schedule contains: 7 x Axura 5 mg 
Svako pakiranje s 28 filmom obloženih tableta za plan liječenja za 4 tjedna sadrži: 7 x Axura 5 mg
The recommended dose of Axura for adults and older people is four pump actuations, equivalent to 20 mg once a day. 
Preporučena doza Axure za odrasle i starije osobe je četiri potiska pumpice, što odgovara 20 mg jednom dnevno.
In these situations the treatment should be carefully supervised, and the clinical benefit of Axura reassessed by your doctor on a regular basis. 
U tim slučajevima liječenje mora biti pažljivo nadzirano, a Vaš liječnik treba redovito ponovno procjenjivati kliničku korist od uzimanja Axure.
The dosing pump must only be used with the Axura solution in the bottle provided, not for other substances or containers. 
Pumpica za doziranje smije se koristiti samo za Axura otopinu u predviđenoj boci, a ne za druge tvari ili spremnike.
Axura belongs to a group of medicines called NMDAreceptor antagonists. 
Axura spada u skupinu lijekova poznatih kao antagonisti NMDA receptora.
- if you are allergic (hypersensitive) to memantine hydrochloride or any of the other ingredients of Axura tablets (listed in section 6). 
- ako ste alergični (preosjetljivi) na memantinklorid ili neki drugi sastojak Axura tableta (naveden u dijelu 6).
The recommended dose of Axura for adults and older people is 20 mg once a day. 
Preporučena doza Axure za odrasle i starije osobe je 20 mg jednom dnevno.
The following Adverse Reactions listed in the Table below have been accumulated in clinical studies with Axura and since its introduction in the market. 
U sljedećoj tablici prikazane su nuspojave prikupljene tijekom kliničkih ispitivanja s Axurom i nakon stavljanja lijeka u promet.
In postmarketing experience these events have been reported in patients treated with Axura. 
Ovi su događaji prijavljeni u postmarketinškom razdoblju kod bolesnika liječenih Axurom.
Axura oral solution is presented as a clear, colourless to light yellowish solution. 
Axura oralna otopina je bistra, bezbojna do svijetlo žućkasta otopina.
Women taking Axura should not breast-feed. 
Žene koje uzimaju Axuru ne smiju dojiti.
EU/1/02/218/016 28 film-coated tablets EU/1/02/218/023 28 film-coated tablets 
EU/1/02/218/016 28 filmom obloženih tableta EU/1/02/218/023 28 filmom obloženih tableta
Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets EU/1/02/218/016 
Axura 5 mg+10 mg+15 mg+20 mg filmom obložene tablete EU/1/02/218/016
For removing the screw cap from the bottle the cap must be turned anticlockwise and unscrewed completely (fig. 1). 
Za uklanjanje zatvarača s navojem s boce, zatvarač se mora okrenuti u smjeru suprotnom od kazaljke na satu i potpuno odvrnuti (sl. 1).
Axura 10 mg film-coated tablets EU/1/02/218/001 
Axura 10 mg filmom obložene tablete EU/1/02/218/001
Axura 20 mg film-coated tablets EU/1/02/218/017 
Axura 20 mg filmom obložene tablete EU/1/02/218/017
Week 2 (day 8-14): The patient should take 1 ml solution (10 mg) equivalent to two pump actuations per day for 7 days. 
2. tjedan (8.-14. dan): Bolesnik treba uzimati 1 ml otopine (10 mg) što odgovara dva potiska pumpice dnevno, tijekom 7 dana.
Axura contains the active substance memantine hydrochloride. 
Axura sadrži djelatnu tvar memantinklorid.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMA) http://www.ema.europa.eu. 
Detaljnije informacije o ovom lijeku dostupne su na web stranici Europske agencije za lijekove (EMA) http://www.ema.europa.eu.
Axura 5 mg, 10 mg, 15 mg, 20 mg tablets 
Axura 5 mg, 10 mg, 15 mg, 20 mg tablete
Axura 20 mg tablets 
Axura 20 mg tablete
Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets The 5 mg film-coated tablets are white to off-white, oval-oblong film-coated tablets with imprint ‘5' on one side and imprint ‘MEM' on the other side. 
Axura 5 mg+10 mg+15 mg+20 mg filmom obložene tablete Filmom obložene tablete od 5 mg su bijele do gotovo bijele, ovalno duguljaste filmom obložene tablete s utisnutom oznakom ‘5' na jednoj strani i ‘MEM' na drugoj strani.
Potassium sorbate Sorbitol E 420 
6.1 Popis pomoćnih tvari kalijev sorbat sorbitol E 420
Axura 10 mg tablets 
Axura 10 mg tablete
EU/1/02/218/022 840 film-coated tablets (20 packs of 42) EU/1/02/218/029 840 film-coated tablets (20 packs of 42) 
EU/1/02/218/022 840 filmom obloženih tableta (20 pakiranja po 42) EU/1/02/218/029 840 filmom obloženih tableta (20 pakiranja po 42)
Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets Each filmcoated tablet contains 5 mg of memantine hydrochloride equivalent to 4.15 mg memantine. 
Axura 5 mg+10 mg+15 mg+20 mg filmom obložene tablete Svaka filmom obložena tableta sadrži 5 mg memantinklorida, što odgovara 4,15 mg memantina.
Detailed information on this medicine is available on the European Medicines Agency (EMA) web side: http://www.ema.europa.eu. 
Detaljnije informacije o ovom lijeku dostupne su na web stranici Europske Agencije za lijekove (EMA) http://www.ema.europa.eu
Week 2 (day 8-14): Take one 10 mg tablet once a day (pale yellow to yellow, oval shaped) for 7 days. 
2. tjedan (8.-14. dan): Uzimajte jednu tabletu od 10 mg jednom dnevno (blijedožutu do žutu, ovalnog oblika) tijekom 7 dana.
You should inform your doctor if you have recently changed or intend to change your diet substantially (e.g. from normal diet to strict vegetarian diet) or if you are suffering from states of renal tubulary acidosis (RTA, an excess of acid-forming substances in the blood due to renal dysfunction (poor kidney function)) or severe infections of the urinary tract (structure that carries urine), as your doctor may need to adjust the dose of your medicine. 
Ako ste nedavno promijenili, ili namjeravate značajno promijeniti svoj način prehrane (npr. s normalne prehrane na strogu vegetarijansku prehranu), ili ako bolujete od stanja renalne tubularne acidoze (RTA - izrazito povećana količina tvari koje tvore kiseline u krvi zbog poremećaja rada bubrega (slaba funkcija bubrega)) ili teških infekcija mokraćnog trakta (struktura kroz koje prolazi mokraća), trebali bi obavijestiti svog liječnika jer će Vam liječnik možda morati prilagoditi dozu lijeka.
Administration of Axura in patients with severe hepatic impairment is not recommended. 
Ne preporučuje se primjena Axure kod bolesnika s teškim oštećenjem jetrene funkcije.
Package leaflet: Information for the user Axura 20 mg film-coated tablets 
Uputa o lijeku: Informacija za korisnika Axura 20 mg filmom obložene tablete memantinklorid
EU/1/02/218/017 14 film-coated tablets EU/1/02/218/018 28 film-coated tablets EU/1/02/218/019 42 film-coated tablets EU/1/02/218/020 56 film-coated tablets EU/1/02/218/021 98 film-coated tablets EU/1/02/218/024 14 film-coated tablets EU/1/02/218/025 28 film-coated tablets EU/1/02/218/026 42 film-coated tablets EU/1/02/218/027 56 film-coated tablets EU/1/02/218/028 98 film-coated tablets 
EU/1/02/218/017 14 filmom obloženih tableta EU/1/02/218/018 28 filmom obloženih tableta EU/1/02/218/019 42 filmom obložene tablete EU/1/02/218/020 56 filmom obloženih tableta EU/1/02/218/021 98 filmom obloženih tableta EU/1/02/218/024 14 filmom obloženih tableta EU/1/02/218/025 28 filmom obloženih tableta EU/1/02/218/026 42 filmom obložene tablete EU/1/02/218/027 56 filmom obloženih tableta EU/1/02/218/028 98 filmom obloženih tableta
From Week 4 on: The patient should take two 10 mg film-coated tablets (20 mg) per day. 
Bolesnik treba uzimati dvije filmom obložene tablete od 10 mg (20 mg) dnevno.
Axura film-coated tablets are available in blister packs of 14 tablets, 28 tablets, 30 tablets, 42 tablets, 50 tablets, 56 tablets, 98 tablets, 100 tablets, 112 tablets and multipacks of 840 (20 packs of 42) tablets, 980 (10 packs of 98) tablets or 1000 (20 packs of 50) tablets. 
Axura filmom obložene tablete dostupne su u pakiranjima s blisterima od 14 tableta, 28 tableta, 30 tableta, 42 tablete, 50 tableta, 56 tableta, 98 tableta, 100 tableta, 112 tableta; i višestrukim pakiranjima od 840 (20 pakiranja od 42) tableta, 980 (10 pakiranja od 98) tableta ili 1000 (20 pakiranja od 50) tableta.
two pump actuations week 3 
2. tjedan dva potiska pumpice
Axura film-coated tablets are available in blister packs of 14 tablets, 28 tablets, 42 tablets, 56 tablets, 98 tablets or in multipacks of 840 (20 x 42) tablets. 
Axura filmom obložene tablete su dostupne u pakiranjima s blisterima od 14 tableta, 28 tableta, 42 tablete, 56 tableta, 98 tableta i višestrukim pakiranjima od 840 (20 pakiranja od 42) tableta.
EU/1/02/218/010 1000 film-coated tablets (20 packs of 50) EU/1/02/218/015 980 film-coated tablets (10 packs of 98) EU/1/02/218/030 840 film-coated tablets (20 packs of 42) 
EU/1/02/218/010 1000 filmom obloženih tableta (20 pakiranja po 50) EU/1/02/218/015 980 filmom obloženih tableta (10 pakiranja po 98) EU/1/02/218/030 840 filmom obloženih tableta (20 pakiranja po 42)
Package leaflet: Information for the user Axura 10 mg film-coated tablets 
Uputa o lijeku: Informacija za korisnika Axura 10 mg filmom obložene tablete memantinklorid
Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets Each pack contains 28 film-coated tablets in 4 PVDC/PE/PVC/Al-blister or PP/Al-blisters with 7 filmcoated tablets of 5 mg, 7 film-coated tablets of 10 mg, 7 film-coated tablets of 15 mg and 7 film-coated tablets of 20 mg. 
Svako pakiranje sadržava 28 filmom obloženih tableta u 4 PVDC/PE/PVC/Al-blistera ili PP/Al-blistera sa 7 filmom obloženih tableta od 5 mg, 7 filmom obloženih tableta od 10 mg, 7 filmom obloženih tableta od 15 mg i 7 filmom obloženih tableta od 20 mg.
Week 3 (day 15-21): Take one 15 mg tablet once a day (grey-orange, oval-oblong) for 7 days. 
3. tjedan (15.-21. dan): Uzimajte jednu tabletu od 15 mg jednom dnevno (sivo-narančastu, duguljasto ovalnu) tijekom 7 dana.
In patients with severe renal impairment (creatinine clearance 5-29 ml/min) daily dose should be 10 mg (1 ml solution, equivalent to two pump actuations) per day. 
Kod bolesnika s teškim oštećenjem bubrebubrežne funkcije (klirens kreatinina 5-29 ml/min) dnevna doza bi trebala biti 10 mg (1 ml otopine, što odgovara dva potiska pumpice) na dan.
EU/1/02/218/012 14 film-coated tablets EU/1/02/218/007 28 film-coated tablets EU/1/02/218/001 30 film-coated tablets EU/1/02/218/013 42 film-coated tablets EU/1/02/218/002 50 film-coated tablets EU/1/02/218/008 56 film-coated tablets EU/1/02/218/014 98 film-coated tablets EU/1/02/218/003 100 film-coated tablets EU/1/02/218/009 112 film-coated tablets 
EU/1/02/218/012 14 filmom obloženih tableta EU/1/02/218/007 28 filmom obloženih tableta EU/1/02/218/001 30 filmom obloženih tableta EU/1/02/218/013 42 filmom obložene tablete EU/1/02/218/002 50 filmom obloženih tableta EU/1/02/218/008 56 filmom obloženih tableta EU/1/02/218/014 98 filmom obloženih tableta EU/1/02/218/003 100 filmom obloženih tableta EU/1/02/218/009 112 filmom obloženih tableta
In clinical trials in mild to severe dementia, involving 1,784 patients treated with Axura and 1,595 patients treated with placebo, the overall incidence rate of adverse reactions with Axura did not differ from those with placebo; the adverse reactions were usually mild to moderate in severity. 
1595 ih je dobivalo placebo sveukupna stopa incidencije nuspojava u skupini liječenoj Axurom nije se razlikovala od stope incidencije nuspojava u skupini koja je primala placebo.
Week 4 (day 22-28): Take one 20 mg tablet per day (grey-red, oval-oblong) for 7 days. 
4. tjedan (22.-28. dan): Uzimajte jednu tabletu od 20 mg dnevno (sivo-crvenu, duguljasto ovalnu) tijekom 7 dana.
From Week 4 on: The patient should take one 20 mg film-coated tablet per day. 
Bolesnik treba uzimati jednu filmom obloženu tabletu od 20 mg dnevno.
EU/1/02/218/005 EU/1/02/218/006 EU/1/02/218/011 
EU/1/02/218/005 EU/1/02/218/006
How to store Axura 
Kako čuvati Axuru
one pump actuation week 2 
1. tjedan jedan potisak pumpice
Very rare (may affect up to 1 in 10,000 users): • Seizures 
Vrlo rijetke (mogu se javiti u do 1 na 10 000 osoba):
The other ingredients are microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, and magnesium stearate, all in the tablet core; and hypromellose, macrogol 400, titanium dioxide (E 171) and iron oxide yellow (E 172) all in the tablet coating. 
Drugi sastojci su: mikrokristalična celuloza,umrežena karmelozanatrij, koloidni bezvodni silicijev dioksid i magnezijev stearat, sve u jezgri tablete; te hipromeloza, makrogol 400, titanijev dioksid (E 171) i žuti željezov oksid (E 172), sve u ovojnici tablete.
The other ingredients are microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate, all in the tablet core; and hypromellose, macrogol 400, titanium dioxide (E 171), iron oxide yellow and red (E 172), all in the tablet coating. 
Drugi sastojci su: mikrokristalična celuloza, umrežena karmelozanatrij, koloidni bezvodni silicijev dioksid i magnezijev stearat, sve u jezgri tablete; te hipromeloza, makrogol 400, titanijev dioksid (E 171) i žuti željezov oksid, žuti i crveni (E 172), sve u ovojnici tablete.
The other ingredients for Axura 5/10/15 and 20 mg film-coated tablets are microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate, all in the tablet core; and hypromellose, macrogol 400, titanium dioxide (E 171) and additional for Axura 10 mg film-coated tablets is iron oxide yellow (E 172) and for Axura 15 mg and Axura 20 mg film-coated tablets are iron oxide yellow and red (E 172), all in the tablet coating. 
umrežena karmelozanatrij, koloidni bezvodni silicijev dioksid i magnezijev stearat sve u jezgri tablete; te hipromeloza, makrogol 400, titanijev dioksid (E 171) i dodatno za Axura 10 mg filmom obložene tablete žuti željezov oksid (E 172), a za Axura 15 mg i Axura 20 mg filmom obložene tablete žuti i crveni željezov oksid (E 172), sve u ovojnici tablete.
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician´s interview based impression of change (CIBIC-plus): p=0.025; Alzheimer´s disease cooperative study - activities of daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002). 
U 6. mjesecu ispitivanja pokazani su povoljni učinci liječenja memantinom u usporedbi s placebom (analiza opaženih slučajeva za promjene bazirane na dojmu kliničara nakon intervjua (CIBIC-plus; engl. the clinician´s interview based impression of change): p=0,025; kooperativno ispitivanje
Axura should be administered orally once a day. 
Axuru treba primjenjivati na usta jedanput na dan.
Package leaflet: Information for the user Axura 5 mg/pump actuation, oral solution 
Uputa o lijeku: Informacija za korisnika Axura 5 mg/potisak, oralna otopina memantinklorid
Do not use Axura after the expiry date which is stated on the carton and the blister after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kartonskoj kutiji i blisteru nakon “Rok valjanosti”.
• There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when memantine is co-administered with HCT or any combination with HCT. 
• Pri istodobnoj primjeni memantina i hidroklorotiazida (HCT-a) ili bilo koje od kombinacija s
Axura 5 mg/pump actuation, oral solution Memantine hydrochloride 
Axura 5 mg/potisak, oralna otopina memantinklorid
Axura 15 mg 7 film-coated tablets. 
Axura 15 mg 7 filmom obloženih tableta.
Axura 5 mg film-coated tablets Axura 10 mg film-coated tablets Axura 15 mg film-coated tablets Axura 20 mg film-coated tablets Memantine hydrochloride 
Axura 5 mg filmom obložene tablete Axura 10 mg filmom obložene tablete Axura 15 mg filmom obložene tablete Axura 20 mg filmom obložene tablete memantinklorid
Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets 
Axura 5 mg+10 mg+15 mg+20 mg filmom obložene tablete
One treatment initiation pack contains 28 tablets in 4 blisters with 7 tablets of Axura 5 mg, 7 tablets of Axura 10 mg, 7 tablets of Axura 15 mg and 7 tablets of Axura 20 mg. 
7 Axura tableta od 10 mg, 7 Axura tableta od 15 mg i 7 Axura tableta od 20 mg.
Do not use Axura after the expiry date which is stated on the carton and the bottle label after the EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kartonskoj kutiji i naljepnici boce nakon “Rok valjanosti”.
Axura 20 mg film-coated tablets Each film-coated tablet contains 20 mg of memantine hydrochloride equivalent to 16.62 mg memantine. 
Axura 20 mg filmom obložene tablete Svaka filmom obložena tableta sadrži 20 mg memantinklorida, što odgovara 16,62 mg memantina.
In patients with moderate renal impairment (creatinine clearance 30-49 ml/min) daily dose should be 10 mg (1 ml solution, equivalent to two pump actuations). 
30-49 ml/min), dnevna doza bi trebala biti 10 mg (1 ml otopine, što odgovara dva potiska pumpice).
Axura 10 mg 7 film-coated tablets. 
Axura 10 mg 7 filmom obloženih tableta.
From Week 4 on: The patient should take 2 ml solution (20 mg) equivalent to four pump actuations once a day. 
Bolesnik treba uzimati 2 ml otopine (20 mg) što odgovara četiri potiska pumpice dnevno.
Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets Axura 20 mg film-coated tablets 
Axura 5 mg+10 mg+15 mg+20 mg filmom obložene tablete Axura 20 mg filmom obložene tablete